血管内皮功能与DN患者并发缺血性心脑血管病的关系

doi:10.3760/cma.j.cn441417-20250114-12017

国际医药卫生导报 ›› 2025, Vol. 31 ›› Issue (12): 2011-2016.DOI: 10.3760/cma.j.cn441417-20250114-12017

血管内皮功能与DN患者并发缺血性心脑血管病的关系

解晖¹ 赵珊² 庞晖¹ 冯萌¹ 李娜¹ 张艳利³

¹陕西中医药大学附属医院检验科，咸阳 712000；²西安交通大学第一附属医院检验科，西安 710061；³陕西中医药大学第二附属医院检验科，咸阳 712000

收稿日期:2025-01-14 出版日期:2025-06-15 发布日期:2025-06-15
通讯作者: 张艳利，Email：fxsyzyl@163.com
基金资助:
陕西省自然科学基础研究计划（2022JM-609）

Relationship between vascular endothelial function and ischemic cardiovascular and cerebrovascular diseases in patients with DN

Xie Hui¹, Zhao Shan², Pang Hui¹, Feng Meng¹, Li Na¹, Zhang Yanli³

¹Clinical Laboratory, Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine, Xianyang 712000, China; ²Clinical Laboratory, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China; ³Clinical Laboratory, Second Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine, Xianyang 712000, China

Received:2025-01-14 Online:2025-06-15 Published:2025-06-15
Contact: Zhang Yanli, Email: fxsyzyl@163.com
Supported by:
Basic Research Plan of Natural Science in Shaanxi (2022JM-609)

摘要/Abstract

摘要：

目的　探讨血管内皮功能与糖尿病肾病（diabetic nephropathy，DN）患者并发缺血性心脑血管病的临床关系。方法　将2020年1月至2023年1月陕西中医药大学附属医院收治的337例DN患者、150例单纯2型糖尿病患者和150例健康体检者依次归入DN组、糖尿病组和健康组。DN组男173例，女164例，年龄（60.89±10.78）岁。糖尿病组男80例，女70例，年龄（60.82±10.63）岁。健康组男79例，女71例，年龄（60.85±10.39）岁。检测其血管内皮功能指标［内皮素（endothelin，ET）、一氧化氮（nitricoxide，NO）、内皮超极化因子（endothelium-dependent hyperpolarizing factor，EDHF）、血管性血友病因子（von Willebrand factor，vWF）、血管内皮生长因子（vascular endothelial growth factor，VEGF）］并进行比较。统计DN患者缺血性心脑血管病发生率。按是否并发缺血性心脑血管病将DN患者分为发生组、未发生组，比较两组血管内皮功能指标与其他临床资料。采用χ²检验、t检验进行统计分析。采用Pearson相关性分析DN患者血管内皮功能指标与缺血性心脑血管病相关性。采用多因素logistic回归模型分析DN患者并发缺血性心脑血管病的影响因素。结果　DN组ET、vWF、VEGF高于糖尿病组、健康组［（62.15±7.59）pg/L比（51.58±6.88）pg/L、（40.82±5.97）pg/L，（728.35±95.48）U/L比（511.58±67.17）U/L、（179.99±22.48）U/L，（174.96±20.18）ng/L比（138.65±18.23）ng/L、（106.78±15.47）ng/L；F=490.30、2 618.32、727.35，均P<0.05］，NO、EDHF低于糖尿病组、健康组［（51.27±7.02）μmol/L比（62.96±8.32）μmol/L、（70.45±9.58）μmol/L，（12.63±2.59）μmol/L比（17.56±3.35）μmol/L、（25.14±4.78）μmol/L；F=328.51、708.23，均P<0.05］；糖尿病组ET、vWF、VEGF高于健康组（均P<0.05），NO、EDHF低于健康组（均P<0.05）。DN患者缺血性心脑血管病发生率为32.94%（111/337）。与未发生组比较，发生组年龄和糖化血红蛋白（glycosylated hemoglobin Alc，HbA1c）、血肌酐（serum creatinine，SCr）、ET、vWF、VEGF水平较高［（70.93±10.05）岁比（55.96±9.24）岁、（12.66±2.67）%比（9.03±2.05）%、（120.56±15.98）μmol/L比（93.57±13.55）μmol/L、（67.95±8.89）pg/L比（59.31±7.45）pg/L、（789.15±80.85）U/L比（698.49±77.66）U/L、（191.36±20.64）ng/L比（166.91±19.75）ng/L；t=13.576、13.783、16.179、9.375、9.936、10.523，均P<0.05］，DN病程较长［（6.34±1.26）年比（4.15±1.03）年；t=17.010，P<0.05］，肾小球滤过率（glomerular filtration rate，GFR）和NO、EDHF水平较低［（77.12±10.68）ml/（min·173 m²）比（96.22±11.48）ml/（min·173 m²）、（44.66±6.82）μmol/L比（54.52±6.24）μmol/L、（9.15±1.78）μmol/L比（14.34±1.85）μmol/L；t=14.683、13.217、24.505，均P<0.05］。DN患者ET、vWF、VEGF与缺血性心脑血管病的发生呈正相关（t=5.152、7.052、6.975，均P<0.001），NO、EDHF与缺血性心脑血管病的发生呈负相关（t=-5.564、-6.272，均P<0.001）；年龄、DN病程、HbA1c、ET、vWF、VEGF是DN患者并发缺血性心脑血管病的危险因素（均P<0.05），GFR、NO、EDHF是保护因素（均P<0.05）。结论　血管内皮功能指标ET、NO、EDHF、vWF、VEGF与DN患者并发缺血性心脑血管病存在相关性，均是DN患者并发缺血性心脑血管病的影响因素。

关键词:

糖尿病肾病, 血管内皮功能, 缺血性心脑血管病, 相关性, 影响因素

Abstract:

Objective　To explore the clinical relationship between vascular endothelial function and ischemic cardiovascular and cerebrovascular diseases in patients with diabetic nephropathy (DN). Methods　Three hundred and thirty-seven patients with DN, 150 patients with type 2 diabetes mellitus, and 150 healthy examinees admitted to Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine from January 2020 to January 2023 were set as a DN group, a diabetes group, and a healthy group, respectively. There were 173 males and 164 females in the DN group; they were (60.89±10.78) years old. There were 80 males and 70 females in the diabetes group; they were (60.82±10.63) years old. There are 79 males and 71 females in the healthy group; they were (60.85±10.39) years old. Their vascular endothelial function indicators [endothelin (ET), nitric oxide (NO), endothelium-dependent hyperpolarizing factor (EDHF), von Willebrand factor (vWF), and vascular endothelial growth factor (VEGF)] were detected and compared. The incidence rate of ischemic cardiovascular and cerebrovascular diseases in the patients with DN was calculated. The patients with DN were divided into an occurrence group and a non-occurrence group according to whether they complicated with ischemic cardiovascular and cerebrovascular diseases, and the levels of vascular endothelial function indicators and other clinical data were compared between the two groups. χ² and t tests were used for the statistical analysis. The correlation between vascular endothelial function indicators and ischemic cardiovascular and cerebrovascular diseases in the patients with DN was analyzed by the Pearson correlation analysis. The multivariate logistic regression model was used to analyze the influencing factors of ischemic cardiovascular and cerebrovascular diseases in the patients with DN. Results　The levels of ET, vWF, and VEGF in the DN group were higher than those in the diabetes group and the healthy group [(62.15±7.59) pg/L vs. (51.58±6.88) pg/L and (40.82±5.97) pg/L, (728.35±95.48) U/L vs. (511.58±67.17) U/L and (179.99±22.48) U/L, and (174.96±20.18) ng/L vs. (138.65±18.23) ng/L and (106.78±15.47) ng/L; F=490.30, 2 618.32, and 727.35; all P<0.05], and the levels of NO and EDHF were lower [(51.27±7.02) μmol/L vs. (62.96±8.32) μmol/L and (70.45±9.58) μmol/L and (12.63±2.59) μmol/L vs. (17.56±3.35) μmol/L and (25.14±4.78) μmol/L; F=328.51 and 708.23; both P<0.05]; the levels of ET, vWF, and VEGF in the diabetes group were higher than those in the healthy group (all P<0.05), and the levels of NO and EDHF were lower (both P<0.05). The incidence rate of ischemic cardiovascular and cerebrovascular diseases in the patients with DN was 32.94% (111/337). The age and levels of glycosylated hemoglobin (HbA1c), serum creatinine (SCr), ET, vWF, and VEGF in the occurrence group were higher than those in the non-occurrence group [(70.93±10.05) years vs. (55.96±9.24) years, (12.66±2.67)% vs. (9.03±2.05)%, (120.56±15.98) μmol/L vs. (93.57±13.55) μmol/L, (67.95±8.89) pg/L vs. (59.31±7.45) pg/L, (789.15±80.85) U/L vs. (698.49±77.66) U/L, and (191.36±20.64) ng/L vs. (166.91±19.75) ng/L; t=13.576, 13.783, 16.179, 9.375, 9.936, and 10.523; all P<0.05], the course of DN was longer [(6.34±1.26) years vs. (4.15±1.03) years; t=17.010; P<0.05], and the glomerular filtration rate (GFR) and levels of NO and EDHF were lower [(77.12±10.68) ml/(min·173 m²) vs. 96.22±11.48) ml/(min·173 m²), (44.66±6.82) μmol/L vs. (54.52±6.24) μmol/L, and (9.15±1.78) μmol/L vs. (14.34±1.85) μmol/L; t=14.683, 13.217, and 24.505; all P<0.05]. ET, vWF and VEGF in the patients with DN were positively correlated with the occurrence of ischemic cardiovascular and cerebrovascular diseases (t=5.152, 7.052, and 6.975; all P<0.001), while NO and EDHF were negatively correlated with the occurrence of ischemic cardiovascular and cerebrovascular diseases (t=-5.564 and -6.272; both P<0.001). Age, course of DN, HbA1c, ET, vWF, and VEGF were the risk factors of the DN patients complicated with ischemic cardiovascular and cerebrovascular diseases (all P<0.05), while GFR, NO, and EDHF were the protective factors (all P<0.05). Conclusion　Endothelial function indicators, such as ET, NO, EDHF, vWF, and VEGF, are correlated with ischemic cardiovascular and cerebrovascular diseases in patients with DN, and are all influencing factors of ischemic cardiovascular and cerebrovascular diseases in patients with DN.

Key words: Diabetic nephropathy, , Vascular endothelial function, , Ischemic cardiovascular and cerebrovascular diseases, , Correlation, , Influencing factors

解晖赵珊庞晖冯萌李娜张艳利. 血管内皮功能与DN患者并发缺血性心脑血管病的关系 [J]. 国际医药卫生导报, 2025, 31(12): 2011-2016.

Xie Hui, Zhao Shan, Pang Hui, Feng Meng, Li Na, Zhang Yanli.

Relationship between vascular endothelial function and ischemic cardiovascular and cerebrovascular diseases in patients with DN [J]. International Medicine and Health Guidance News, 2025, 31(12): 2011-2016.

参考文献

[1]van Raalte DH, Bjornstad P, Cherney DZI, et al. Combination therapy for kidney disease in people with diabetes mellitus[J]. Nat Rev Nephrol, 2024, 20(7): 433-446. DOI:10.1038/s41581-024-00827-z.

[2]Wheeler DC, Stefánsson BV, Jongs N, et al. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial[J]. Lancet Diabetes Endocrinol, 2021, 9(1): 22-31. DOI: 10.1016/S2213-8587(20)30369-7.

[3]Barzilay JI, Farag YMK, Durthaler J. Albuminuria: an underappreciated risk factor for cardiovascular disease [J]. J Am Heart Assoc, 2024, 13(2): e030131. DOI:10.1161/JAHA.123.030131.

[4]Saito Y, Tanaka A, Node K, et al. Uric acid and cardiovascular disease: a clinical review[J]. J Cardiol, 2021, 78(1): 51-57. DOI:10.1016/j.jjcc.2020.12.013.

[5]陈姝漫,宾文凯,倪德芳,等.蛋白酶活化受体1在血管内皮损伤中的作用[J].医学研究杂志, 2023, 52(12): 194-197. DOI: 10.11969/j.issn.1673-548X.2023.12.039.

[6]辛艳峰,吴振华,郭莉清,等.稳定型冠心病患者vWF、ET-1、sICAM-1水平对急性心肌梗死发病风险的联合预测价值[J].解放军医药杂志, 2022, 34(2):74-78. DOI:10.3969/j.issn.2095-140X.2022.02.017.

[7]朱永平,郭小军.血清HbA1c,VCAM-1,VEGF表达水平与后循环脑梗死的相关性[J].贵州医药, 2024, 48(4): 620-622. DOI: 10.3969/j.issn.1000-744X.2024.04.041.

[8]中华医学会糖尿病学分会微血管并发症学组.中国糖尿病肾脏疾病防治临床指南[J].中华糖尿病杂志, 2019, 11(1): 15-28. DOI: 10.3760/cma.j.issn.1674-5809.2019.01.004.

[9]中华医学会糖尿病学分会.中国2型糖尿病防治指南(2017年版)[J].中华糖尿病杂志, 2018, 10(1): 4-67. DOI: 10.3760/cma.j.issn.1674-5809.2018.01.003.

[10]Xu S, Ilyas I, Little PJ, et al. Endothelial dysfunction in atherosclerotic cardiovascular diseases and beyond: from mechanism to pharmacotherapies[J]. Pharmacol Rev, 2021, 73(3): 924-967. DOI: 10.1124/pharmrev. 120. 000096.

[11]苗燕.老年2型糖尿病肾病并发心脑血管疾病相关危险因素分析[J].陕西医学杂志, 2016, 45(12):1651-1652. DOI: 10.3969/j.issn.1000-7377.2016.12.039.

[12]卫志锋,韩小丽,智云霞,等.血清外泌体中miR-301a与糖尿病肾病腹膜透析后心脑血管事件的相关性[J].西安交通大学学报(医学版), 2023, 44(3):421-426. DOI: 10.7652/jdyxb202303013.

[13]Xu S, Ilyas I, Little PJ, et al. Endothelial dysfunction in atherosclerotic cardiovascular diseases and beyond: from mechanism to pharmacotherapies[J]. Pharmacol Rev, 2021, 73(3): 924-967. DOI:10.1124/pharmrev. 120.000096.

[14]Genovesi S, Giussani M, Orlando A, et al. Relationship between endothelin and nitric oxide pathways in the onset and maintenance of hypertension in children and adolescents [J]. Pediatr Nephrol, 2022, 37(3):537-545. DOI: 10.1007/s00467-021-05144-2.

[15]Shimokawa H, Godo S. Nitric oxide and endothelium-dependent hyperpolarization mediated by hydrogen peroxide in health and disease[J]. Basic Clin Pharmacol Toxicol, 2020, 127(2): 92-101. DOI:10.1111/bcpt.13377.

[16]Panda SP, Reddy PH, Gorla US, et al. Neuroinflammation and neovascularization in diabetic eye diseases (DEDs): identification of potential pharmacotherapeutic targets[J]. Mol Biol Rep, 2023, 50(2):1857-1869. DOI: 10.1007/s11033-022-08113-6.

[17]Schiborn C, Schulze MB. Precision prognostics for the development of complications in diabetes[J]. Diabetologia, 2022, 65(11): 1867-1882. DOI: 10.1007/s00125-022-05731-4.

[18]靳晖.慢性肾脏病患者心血管疾病的发生规律及相关性研究[D].济南:山东大学, 2014.

[19]赵耀,吴宏.颈动脉和心脏超声指标与2型糖尿病患者心脑血管疾病风险的关系[J].国际医药卫生导报, 2023, 29(5): 623-627. DOI: 10.3760/cma.j.issn.1007-1245. 2023.05.007.

[20]杨峰,王毓虹. Hcy,UA,HbA1c,踝臂指数联合检测对糖尿病并发心脑血管疾病的预测价值[J].深圳中西医结合杂志, 2023, 33(10): 64-67. DOI: 10.16458/j.cnki.1007-0893. 2023.10.020.

血管内皮功能与DN患者并发缺血性心脑血管病的关系

Relationship between vascular endothelial function and ischemic cardiovascular and cerebrovascular diseases in patients with DN

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	杨月太贾本治. 骨水泥/椎体体积比与经皮椎体成形术后邻近椎体压缩骨折的相关性分析 [J]. 国际医药卫生导报, 2025, 31(9): 1421-1425.
[2]	刘庆任文娟钟红平. 川崎病患儿静脉注射免疫球蛋白耐药的影响因素及冠状动脉损害情况 [J]. 国际医药卫生导报, 2025, 31(9): 1451-1456.
[3]	张婷郭淋张驰付瑞崔治权康晓刚. 青少年双相情感障碍患者血脂水平与区域性脑结构的相关性研究 [J]. 国际医药卫生导报, 2025, 31(9): 1538-1543.
[4]	任常青李惠平杜振萍王立新伍世表. 急性脑出血患者住院时间延长的影响因素分析 [J]. 国际医药卫生导报, 2025, 31(7): 1157-1161.
[5]	古丽妮尕尔·阿里木阎朝光阿不都外力·阿不都克里木麦麦提江·阿依丁陈长春马晓玲陈晖. 反流性食管炎与幽门螺杆菌感染的关系探讨[J]. 国际医药卫生导报, 2025, 31(6): 882-885.
[6]	高文浩赵蕊李桂林. 颈深部感染患者临床特征及高危并发症的影响因素分析 [J]. 国际医药卫生导报, 2025, 31(6): 945-949.
[7]	魏歆林杨会会刘林波熊朝亮. 尿外泌体miR-155及脂水平与糖尿病肾病严重程度的相关性分析 [J]. 国际医药卫生导报, 2025, 31(6): 949-954.
[8]	薛媛王东张杰闫娟李二乐拓明祥. 中耳炎患者耳内镜手术后复发情况及预测模型构建 [J]. 国际医药卫生导报, 2025, 31(6): 1041-1046.
[9]	思雅芳刘瑜瑜曹丽. 不同剂量利妥昔单抗治疗特发性膜性肾病的效果及复发影响因素分析 [J]. 国际医药卫生导报, 2025, 31(5): 723-728.
[10]	陈聪玲王婷张进召. 慢性阻塞性肺疾病急性加重期患者营养风险列线图模型的建立与验证 [J]. 国际医药卫生导报, 2025, 31(5): 771-779.
[11]	聂清华李晓龙朱博代志明. 剖宫产产妇麻醉后发生低血压的影响因素分析及列线图模型构建 [J]. 国际医药卫生导报, 2025, 31(4): 627-632.
[12]	翟夏康启赵学飞李敏杰陈敏娜董欢乐董静. 基于决策树算法构建急性心肌梗死患者PCI术后血运重建的风险预测方案 [J]. 国际医药卫生导报, 2025, 31(3): 370-376.
[13]	陈琛王燕平. 心脏体外循环术后口渴现状及影响因素分析 [J]. 国际医药卫生导报, 2025, 31(3): 396-400.
[14]	付瑞舒忙巧王文栋郭新强王新荣康晓刚. 抑郁症伴精神病性症状与儿童期虐待的相关性分析及预测模型构建 [J]. 国际医药卫生导报, 2025, 31(3): 425-429.
[15]	刘哲汤文郁李力潘建萍. 慢性意识障碍患者定量脑电图特征与意识障碍程度及转归的关系 [J]. 国际医药卫生导报, 2025, 31(2): 236-241.